Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.
A Johns Hopkins Children's Center study of children and youth with diabetes concludes that so-called autonomous artificial intelligence (AI) diabetic eye exams significantly increase completion rates of screenings designed to prevent potentially blinding diabetes eye diseases (DED).
"DeepDR Plus," a deep learning system, accurately predicts diabetic retinopathy progression up to five years using fundus images, offering potential for personalized screening and management in diabetic patients.
Extending the annual screen to two years for people in England considered at low risk of diabetic eye disease could lead to critical treatment delays and sight loss, according to research led by St George's, University of London and Moorfields Eye Hospital NHS Foundation Trust and involving Kingston University, London researchers and academics.
Extending the annual screen by a year for people in England considered to be at low risk of diabetic eye disease (diabetic retinopathy) could risk critical treatment delays and/or sight loss, suggests a large, real world data study, published online in the British Journal of Ophthalmology.
People with diabetes who experience periods of low blood sugar — a common occurrence in those new to blood sugar management — are more likely to have worsening diabetic eye disease.
St George's, University of London and Moorfields Eye Hospital NHS Foundation Trust are leading a half a million pound project on artificial intelligence (AI), funded by NHSX and the Health Foundation, and enabled by the National Institute for Health Research.
People with type 2 diabetes diagnosed during youth have a high risk of developing complications at early ages and have a greater chance of multiple complications within 15 years after diagnosis.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
Diabetes continues to be the leading cause of new cases of blindness among adults in the United States. But the current shortage of eye-care providers would make it impossible to keep up with demand to provide the requisite annual screenings for this population.
Surgical and injectable drug approaches are equally effective for treatment of bleeding inside the eye from proliferative diabetic retinopathy (PDR), according to a National Eye Institute (NEI)-supported clinical study from the DRCR Retina Network (DRCR.net).
A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.
Results from the largest study of artificial intelligence use in the English Diabetic Eye Screening Programme (DESP), have shown that the technology can accurately detect serious eye disease among those with diabetes (retinopathy) and could halve the human workload associated with screening for diabetic eye disease, saving millions of pounds annually.
A lengthy-named gene called Elongation of Very Long Chain Fatty Acids Protein 2 or ELOVL2 is an established biomarker of age.
A survey conducted by The Harris Poll has uncovered key gaps in American's knowledge of eye health, and what they don't know is putting them at risk of vision loss.
Health products powered by artificial intelligence, or AI, are streaming into our lives, from virtual doctor apps to wearable sensors and drugstore chatbots.
With $9.7 million in funding from the National Eye Institute, researchers at the University of Illinois at Chicago will study the impact of chronic eye disease among Latinos.
A new study presented at the Annual Meeting of the American Academy of Ophthalmologists (AAO) on October 14, 2019 reports an astonishing 95.% yield when artificial intelligence (AI) is used to screen a real life population for diabetic retinopathy.
The number of older Americans with low vision is expected to double in the coming years, as more people live longer.
This HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).
Researchers at Joslin Diabetes Center have shown that a protein found in the eye can protect against and potentially treat diabetic eye disease.